Cargando…

Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status

INTRODUCTION: Systemic sclerosis (SSc) is a connective tissue disorder characterized by tissue hypoxia due to vascular changes and excessive fibrosis of the skin and internal organs. Damage to blood vessels and endothelium, as well as imbalance of vascular homeostasis, impairment of angiogenesis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziankowska-Bartkowiak, Bożena, Gerlicz-Kowalczuk, Zofia, Waszczykowska, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258685/
https://www.ncbi.nlm.nih.gov/pubmed/22291739
http://dx.doi.org/10.5114/aoms.2011.20610
_version_ 1782221292391366656
author Dziankowska-Bartkowiak, Bożena
Gerlicz-Kowalczuk, Zofia
Waszczykowska, Elżbieta
author_facet Dziankowska-Bartkowiak, Bożena
Gerlicz-Kowalczuk, Zofia
Waszczykowska, Elżbieta
author_sort Dziankowska-Bartkowiak, Bożena
collection PubMed
description INTRODUCTION: Systemic sclerosis (SSc) is a connective tissue disorder characterized by tissue hypoxia due to vascular changes and excessive fibrosis of the skin and internal organs. Damage to blood vessels and endothelium, as well as imbalance of vascular homeostasis, impairment of angiogenesis and vasculogenesis are observed in the course of the disease. The aim of the study was to investigate the pro-angiogenic factors angiogenin and SDF-1α in patients with SSc. MATERIAL AND METHODS: Serum samples were collected from 50 patients with dSSc (diffuse SSc) and lSSc (limited SSc) and from 38 patients used as a healthy control group. We explored: 1) how the serum concentrations of SDF-1α and angiogenin differ in the investigated groups; 2) the correlation among chemokines in SSc and the duration of the disease, Raynaud’s phenomenon, sclerosis of the skin and TSS (total skin score). RESULTS: Patients with SSc showed statistically significantly higher serum angiogenin concentration and there was no correlation between duration of the disease and Raynaud’s phenomenon, skin sclerosis or TSS. There was also no difference or no correlation between serum level of SDF-1α and the investigated groups. CONCLUSIONS: The increase in angiogenin concentration in the serum in patients with SSc may confirm endothelial damage caused by hypoxia and reduced vascular perfusion due to the course of SSc without contributing to compensatory revascularization.
format Online
Article
Text
id pubmed-3258685
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-32586852012-01-30 Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status Dziankowska-Bartkowiak, Bożena Gerlicz-Kowalczuk, Zofia Waszczykowska, Elżbieta Arch Med Sci Clinical Research INTRODUCTION: Systemic sclerosis (SSc) is a connective tissue disorder characterized by tissue hypoxia due to vascular changes and excessive fibrosis of the skin and internal organs. Damage to blood vessels and endothelium, as well as imbalance of vascular homeostasis, impairment of angiogenesis and vasculogenesis are observed in the course of the disease. The aim of the study was to investigate the pro-angiogenic factors angiogenin and SDF-1α in patients with SSc. MATERIAL AND METHODS: Serum samples were collected from 50 patients with dSSc (diffuse SSc) and lSSc (limited SSc) and from 38 patients used as a healthy control group. We explored: 1) how the serum concentrations of SDF-1α and angiogenin differ in the investigated groups; 2) the correlation among chemokines in SSc and the duration of the disease, Raynaud’s phenomenon, sclerosis of the skin and TSS (total skin score). RESULTS: Patients with SSc showed statistically significantly higher serum angiogenin concentration and there was no correlation between duration of the disease and Raynaud’s phenomenon, skin sclerosis or TSS. There was also no difference or no correlation between serum level of SDF-1α and the investigated groups. CONCLUSIONS: The increase in angiogenin concentration in the serum in patients with SSc may confirm endothelial damage caused by hypoxia and reduced vascular perfusion due to the course of SSc without contributing to compensatory revascularization. Termedia Publishing House 2011-02 2011-03-08 /pmc/articles/PMC3258685/ /pubmed/22291739 http://dx.doi.org/10.5114/aoms.2011.20610 Text en Copyright © 2011 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Dziankowska-Bartkowiak, Bożena
Gerlicz-Kowalczuk, Zofia
Waszczykowska, Elżbieta
Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title_full Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title_fullStr Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title_full_unstemmed Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title_short Angiogenin and SDF-1α serum concentration in patients with systemic sclerosis in relation to clinical status
title_sort angiogenin and sdf-1α serum concentration in patients with systemic sclerosis in relation to clinical status
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258685/
https://www.ncbi.nlm.nih.gov/pubmed/22291739
http://dx.doi.org/10.5114/aoms.2011.20610
work_keys_str_mv AT dziankowskabartkowiakbozena angiogeninandsdf1aserumconcentrationinpatientswithsystemicsclerosisinrelationtoclinicalstatus
AT gerliczkowalczukzofia angiogeninandsdf1aserumconcentrationinpatientswithsystemicsclerosisinrelationtoclinicalstatus
AT waszczykowskaelzbieta angiogeninandsdf1aserumconcentrationinpatientswithsystemicsclerosisinrelationtoclinicalstatus